Skip to main content

11-11-2020 | ACR 2020 | Conference coverage | Video

The potential impact of tofacitinib on AS treatment

Marina Magrey comments on a phase 3 trial of the JAK inhibitor tofacitinib versus placebo in patients with ankylosing spondylitis (4:25).

Read transcript